Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents

This article sheds light on the various scaffolds that can be used in the designing and development of novel synthetic compounds to create DPP-4 inhibitors for the treatment of type 2 diabetes mellitus (T2DM). This review highlights a variety of scaffolds with high DPP-4 inhibition activity, such as pyrazolopyrimidine, tetrahydro pyridopyrimidine, uracil-based benzoic acid and esters, triazole-based, fluorophenyl-based, glycinamide, glycolamide, β-carbonyl 1,2,4-triazole, and quinazoline motifs. The article further explains that the potential of the compounds can be increased by substituting atoms such as fluorine, chlorine, and bromine. Docking of existing drugs like sitagliptin, saxagliptin, and vildagliptin was done using Maestro 12.5, and the interaction with specific residues was studied to gain a better understanding of the active sites of DPP-4. The structural activities of the various scaffolds against DPP-4 were further illustrated by their inhibitory concentration (IC50) values. Additionally, various synthesis schemes were developed to make several commercially available DPP4 inhibitors such as vildagliptin, sitagliptin and omarigliptin. In conclusion, the use of halogenated scaffolds for the development of DPP-4 inhibitors is likely to be an area of increasing interest in the future.

[1]  Y. Khan,et al.  DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature , 2023, Frontiers in Molecular Biosciences.

[2]  Kailash Chandra,et al.  Pyrazole scaffold‐based derivatives: A glimpse of α‐glucosidase inhibitory activity, SAR, and route of synthesis , 2023, Archiv der Pharmazie.

[3]  A. M. Jones,et al.  Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl‐peptidase IV inhibitors (DPP4i): Can polypharmacology help explain? , 2022, medRxiv.

[4]  F. Ping,et al.  Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials , 2022, BMJ.

[5]  Pancreatic safety of DPP-4 inhibitors in type 2 diabetes millitus , 2022, Medicine.

[6]  Lu Zhao,et al.  Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis , 2022, PloS one.

[7]  Helmy M. Sakr REVIEW ON THE SIGNIFICANCE OF QUINAZOLINONE DERIVATIVES AS POTENT ANTIHYPERGLYCEMIC AGENTS , 2022, Al-Azhar Journal of Pharmaceutical Sciences.

[8]  K. Kridin,et al.  Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation , 2022, Archives of Dermatological Research.

[9]  M. Anwar,et al.  New quinoxaline compounds as DPP-4 inhibitors and hypoglycemics: design, synthesis, computational and bio-distribution studies , 2021, RSC advances.

[10]  Xiaoyan Deng,et al.  Identification and structure-activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. , 2021, European journal of medicinal chemistry.

[11]  Shubham Kumar,et al.  A review upon medicinal perspective and designing rationale of DPP-4 inhibitors. , 2021, Bioorganic & medicinal chemistry.

[12]  R. Omelka,et al.  Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus , 2021, Pharmaceuticals.

[13]  A. Šmelcerović,et al.  Structure-Activity Relationship Analysis of Cocrystallized Gliptin-like Pyrrolidine, Trifluorophenyl, and Pyrimidine-2,4-Dione Dipeptidyl Peptidase-4 Inhibitors. , 2021, Journal of Medicinal Chemistry.

[14]  Chih-Hao Lu,et al.  Design, synthesis and biological evaluation of glycolamide, glycinamide, and β-amino carbonyl 1,2,4-triazole derivatives as DPP-4 inhibitors. , 2021, Bioorganic chemistry.

[15]  S. Mittal,et al.  GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus. , 2021, Bioorganic chemistry.

[16]  A. Mourad,et al.  Novel Potent and Selective DPP-4 Inhibitors: Design, Synthesis and Molecular Docking Study of Dihydropyrimidine Phthalimide Hybrids , 2021, Pharmaceuticals.

[17]  Hyo‐Soo Kim,et al.  Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis , 2021, Journal of lipid and atherosclerosis.

[18]  M. D. Altıntop,et al.  Pyrazole Incorporated New Thiosemicarbazones: Design, Synthesis and Investigation of DPP-4 Inhibitory Effects , 2020, Molecules.

[19]  Honglin Li,et al.  Design, Synthesis and SAR Studies of Novel and Potent Dipeptidyl Peptidase 4 Inhibitors , 2020, Chinese Journal of Chemistry.

[20]  P. He,et al.  Design, Synthesis and Evaluation of a Series of Novel Super-long Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes. , 2020, Journal of medicinal chemistry.

[21]  Y. Reddy,et al.  Design, synthesis and biological evaluation of novel 1,2,3-triazole-based xanthine derivatives as DPP-4 inhibitors , 2020, Journal of Chemical Sciences.

[22]  O. Blacque,et al.  Crystal structure, Hirshfeld surface analysis and DFT studies of 5-(adamantan-1-yl)-3-[(4-chlorobenzyl)sulfanyl]-4-methyl-4H-1,2,4-triazole, a potential 11β-HSD1 inhibitor , 2019, Scientific Reports.

[23]  K. Makrilakis The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect , 2019, International journal of environmental research and public health.

[24]  M. Anwar,et al.  Design, Synthesis and Biological Evaluation of Spiro Cyclohexane-1,2- Quinazoline Derivatives as Potent Dipeptidyl Peptidase IV Inhibitors. , 2019, Mini reviews in medicinal chemistry.

[25]  M. Zheng,et al.  Hydrolytic Metabolism of Cyanopyrrolidine DPP-4 Inhibitors Mediated by Dipeptidyl Peptidases , 2018, Drug Metabolism and Disposition.

[26]  D. Drucker,et al.  Fibroblast activation protein is dispensable for control of glucose homeostasis and body weight in mice , 2018, Molecular metabolism.

[27]  S. Houser,et al.  Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control , 2018, Front. Physiol..

[28]  C. Li,et al.  Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors. , 2018, Bioorganic & medicinal chemistry letters.

[29]  Xiangqian Li,et al.  Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. , 2018, European journal of medicinal chemistry.

[30]  Tahereh Arablou,et al.  Polyphenols and their effects on diabetes management: A review , 2017, Medical journal of the Islamic Republic of Iran.

[31]  Huibin Zhang,et al.  Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors. , 2017, Bioorganic chemistry.

[32]  G. Giovenzana,et al.  A concise and efficient synthesis of vildagliptin , 2017 .

[33]  L. Tan,et al.  Asymmetric Formal Synthesis of the Long-Acting DPP-4 Inhibitor Omarigliptin. , 2017, The Journal of organic chemistry.

[34]  D. Hardie,et al.  The mechanisms of action of metformin , 2017, Diabetologia.

[35]  P. M. Vasil’ev,et al.  New dipeptidyl peptidase 4 inhibitors among adamantane derivatives , 2017, Russian Journal of Bioorganic Chemistry.

[36]  Yan Zhu,et al.  Synthesis of phenylpyridine derivatives and their biological evaluation toward dipeptidyl peptidase-4 , 2017, Chemistry of Heterocyclic Compounds.

[37]  H. Shimano,et al.  Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs – An Ab Initio Fragment Molecular Orbital Study , 2016, PloS one.

[38]  Manish Maladkar,et al.  Teneligliptin: Heralding Change in Type 2 Diabetes , 2016 .

[39]  Jinsong Hao,et al.  Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP-4 Inhibitors for the Treatment of Type 2 Diabetes. , 2016, ACS medicinal chemistry letters.

[40]  Jeremy P. Scott,et al.  Evolution of a Manufacturing Route to Omarigliptin, A Long-Acting DPP-4 Inhibitor for the Treatment of Type 2 Diabetes , 2015 .

[41]  W. Duan,et al.  Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus , 2015, Clinical and experimental pharmacology & physiology.

[42]  Huibin Zhang,et al.  Design, Synthesis and Biological Evaluation of Imidazo[1,2‐a]pyridine Derivatives as Novel DPP‐4 Inhibitors , 2015, Chemical biology & drug design.

[43]  Mitsuru Oka,et al.  Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions , 2015, Journal of enzyme inhibition and medicinal chemistry.

[44]  Weiliang Zhu,et al.  Design, Synthesis, and Pharmacological Evaluation of Fused β-Homophenylalanine Derivatives as Potent DPP-4 Inhibitors. , 2015, ACS medicinal chemistry letters.

[45]  Laurent Pellegatti,et al.  Synthesis of Vildagliptin Utilizing Continuous Flow and Batch Technologies , 2015 .

[46]  Hongmei Song,et al.  Synthesis of New DPP-4 Inhibitors Based on a Novel Tricyclic Scaffold. , 2015, ACS medicinal chemistry letters.

[47]  Ebtehal S. Al-Abdullah,et al.  Antimicrobial and Hypoglycemic Activities of Novel N-Mannich Bases Derived from 5-(1-Adamantyl)-4-substituted-1,2,4-triazoline-3-thiones , 2014, International journal of molecular sciences.

[48]  A. Farooqi,et al.  Alogliptin – a new DPP‐4 inhibitor for type 2 diabetes , 2014 .

[49]  S. B. Katti,et al.  Sixteen-years of clinically relevant dipeptidyl peptidase-IV (DPP-IV) inhibitors for treatment of type-2 diabetes: a perspective. , 2014, Current medicinal chemistry.

[50]  Jun Xu,et al.  Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes. , 2014, ACS medicinal chemistry letters.

[51]  B. Ahrén,et al.  Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors , 2014, Diabetes.

[52]  Kathy Lyons,et al.  Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. , 2014, Journal of medicinal chemistry.

[53]  L. Juillerat-Jeanneret Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else? , 2014, Journal of medicinal chemistry.

[54]  M. Ghate,et al.  Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. , 2014, European journal of medicinal chemistry.

[55]  D. Giugliano,et al.  Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin , 2013, Drug design, development and therapy.

[56]  P. Kaur,et al.  Synthesis, Evaluation and Molecular Docking of Prolyl‐Fluoropyrrolidine Derivatives as Dipeptidyl Peptidase IV Inhibitors , 2013, Chemical biology & drug design.

[57]  Shinichi Ishii,et al.  A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. , 2013, Biochemical and biophysical research communications.

[58]  F. Folli,et al.  The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus , 2013, Archives of medical science : AMS.

[59]  A. Joerger,et al.  Principles and applications of halogen bonding in medicinal chemistry and chemical biology. , 2013, Journal of medicinal chemistry.

[60]  D. Stewart,et al.  Berry components inhibit α-glucosidase in vitro: synergies between acarbose and polyphenols from black currant and rowanberry. , 2012, Food chemistry.

[61]  C. Deacon,et al.  Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis , 2012, Diabetes, obesity & metabolism.

[62]  Hualiang Jiang,et al.  Synthesis, Structure–Activity Relationship, and Pharmacophore Modeling Studies of Pyrazole‐3‐Carbohydrazone Derivatives as Dipeptidyl Peptidase IV Inhibitors , 2012, Chemical biology & drug design.

[63]  Mohamed Lotfy,et al.  Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus , 2011, The open medicinal chemistry journal.

[64]  J. Holst,et al.  Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. , 2011, Endocrinology.

[65]  J. Holst,et al.  Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. , 2011, The Journal of clinical endocrinology and metabolism.

[66]  L. Hamann,et al.  Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes. , 2010, Bioorganic & medicinal chemistry letters.

[67]  D. D’Alessio,et al.  Effect of Endogenous GLP-1 on Insulin Secretion in Type 2 Diabetes , 2010, Diabetes.

[68]  Gregory S Jones,et al.  Preparation of Saxagliptin, a Novel DPP-IV Inhibitor , 2009 .

[69]  Feng Xu,et al.  Highly efficient asymmetric synthesis of sitagliptin. , 2009, Journal of the American Chemical Society.

[70]  G. Scapin,et al.  Discovery of new binding elements in DPP-4 inhibition and their applications in novel DPP-4 inhibitor design. , 2008, Bioorganic & medicinal chemistry letters.

[71]  M. Pal,et al.  Synthesis of (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile: A key intermediate for dipeptidyl peptidase IV inhibitors , 2008, Beilstein journal of organic chemistry.

[72]  D. Kassel,et al.  Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[73]  W. Metzler,et al.  Involvement of DPP‐IV catalytic residues in enzyme–saxagliptin complex formation , 2008, Protein science : a publication of the Protein Society.

[74]  I. Idris,et al.  Dipeptidyl peptidase‐IV inhibitors: a major new class of oral antidiabetic drug , 2007, Diabetes, obesity & metabolism.

[75]  G. Scapin,et al.  (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[76]  O. Schmitz,et al.  GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[77]  Biching Sang,et al.  Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation , 2004, Protein science : a publication of the Protein Society.

[78]  T. Hughes,et al.  1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. , 2003, Journal of medicinal chemistry.

[79]  Yuyuan Li,et al.  Design and synthesis of tetrahydropyridopyrimidine derivatives as dual GPR119 and DPP-4 modulators. , 2019, Bioorganic chemistry.

[80]  S. Devineni,et al.  Facile new industrial process for synthesis of teneligliptin through new intermediates and its optimization with control of impurities , 2017, Research on Chemical Intermediates.

[81]  W. Haq,et al.  Discovery of 17 Gliptins in 17-Years of Research for the Treatment of Type 2 Diabetes: A Synthetic Overview , 2014 .

[82]  D. Zyl The mechanism of action of oral antidiabetic drugs : A review of recent literature , 2008 .